Nottingham, UK – 21st April 2004 – Scancell Ltd, the pioneering Nottingham-based therapeutics company that is harnessing the power of the immune system to fight cancer, has announced the appointment of Dr Michael Capaldi as Chief Executive Officer. Dr Capaldi brings to Scancell extensive commercial and management experience in the pharmaceutical and life sciences industries, together with a strong scientific background.
Commenting on his new position, Dr Capaldi said:
“Scancell is at an exciting stage of development and I look forward to contributing to the future success of the Company. I am convinced that Scancell can make a major contribution towards developing new cancer therapies that harness the power of the immune system.”
Dr Capaldi was previously CEO of Synaptica Ltd where he served from 2000. He has a broad working knowledge of the biopharmaceutical industry with a strong commercial bias, combined with a solid understanding of pharmaceutical discovery and development. He has first hand experience of raising capital from private and public markets to fund early stage biotechnology companies including an IPO of Core Group as a full listing on the London Stock Exchange (LSE) in 1997. He has over 20 years experience in the pharmaceutical and life sciences industry within the UK, Europe and the USA, including over 17 years commercial and general management experience gained with SmithKline Beecham plc, Amersham plc, Core Group plc, Oxford Asymmetry plc and Synaptica Ltd. Prior to this he gained five years multidisciplinary research experience in academic and applied pharmaceutical research and management with Ciba-Geigy.
Michael holds a PhD in Medical Biophysics from the University of Manchester, and has experience of both academic and applied pharmaceutical research. Welcoming Dr Capaldi to the Company, Chairman Nigel Evans said:
“Michael brings significant management, commercial and fund raising experience to Scancell, which will be invaluable as the Company commercialises its therapeutic antibodies and it’s ImmunoBody® technology. Monoclonal antibody technology promises considerable hope for the treatment and prevention of cancer.”
<p> <a href="http://www.proactiveinvestors.co.uk/LON:SCLP/Scancell-Holdings-Plc/" class="companyPopupTrigger" rel="3362">Scancell Holdings Plc</a> (<a href="http://www.proactiveinvestors.co.uk/LON:SCLP/Scancell-Holdings-Plc/" class="companyPopupTrigger" rel="3362">LON:SCLP</a>) has confirmed it will kick off a phase II clinical trial of its potentially breakthrough cancer treatment in the second half.</p> <p> CEO Richard Goodfellow also tells Proactive's Andrew Scott they've found a partner to help them with a phase I/II clinical study of SCIB2 for patients with lung cancer.</p> Wed, 01 Feb 2017 09:53:00
The update was provided as Scancell served up its financial results for the six months ended October 31.Tue, 31 Jan 2017 08:01:00